scholarly journals Constitutive proteasomal degradation of TWIST-1 in epithelial–ovarian cancer stem cells impacts differentiation and metastatic potential

Oncogene ◽  
2012 ◽  
Vol 32 (1) ◽  
pp. 39-49 ◽  
Author(s):  
G Yin ◽  
A B Alvero ◽  
V Craveiro ◽  
J C Holmberg ◽  
H-H Fu ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Stem Cells ◽  
Cancer Stem Cells ◽  
Epithelial Ovarian Cancer ◽  
Metastatic Potential ◽  
Proteasomal Degradation ◽  
Ovarian Cancer Stem Cells ◽  
Twist 1

Abstract 3405: Epithelial ovarian cancer stem cells are the source of metastatic progenitor cells

2011 ◽  
Author(s):  
Gang Yin ◽  
Vinny Craveiro ◽  
Jennie Holmberg ◽  
Han-Hsuan Fu ◽  
Michael K. Montagna ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Stem Cells ◽  
Cancer Stem Cells ◽  
Epithelial Ovarian Cancer ◽  
Progenitor Cells ◽  
Ovarian Cancer Stem Cells

scholarly journals Prevalence of Epithelial Ovarian Cancer Stem Cells Correlates with Recurrence in Early-Stage Ovarian Cancer

2011 ◽  
Vol 2011 ◽  
pp. 1-12 ◽  
Author(s):  
Karina Dahl Steffensen ◽  
Ayesha B. Alvero ◽  
Yang Yang ◽  
Marianne Waldstrøm ◽  
Pei Hui ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Stem Cells ◽  
Cancer Stem Cells ◽  
Epithelial Ovarian Cancer ◽  
Early Stage ◽  
Progression Free Survival ◽  
Ovarian Cancer Stem Cells ◽  
Free Survival ◽  
And Function ◽  
Early Stage Ovarian Cancer

Epithelial ovarian cancer stem cells (EOC stem cells) have been associated with recurrence and chemoresistance. CD44 and CK18 are highly expressed in cancer stem cells and function as tools for their identification and characterization. We investigated the association between the number of CD44+ EOC stem cells in ovarian cancer tumors and progression-free survival. EOC stem cells exist as clusters located close to the stroma forming the cancer stem cell “niche”. 17.1% of the samples reveled high number of CD44+ EOC stem cells (>20% positive cells). In addition, the number of CD44+ EOC stem cells was significantly higher in patients with early-stage ovarian cancer (FIGO I/II), and it was associated with shorter progression-free survival (P=0.026). This study suggests that quantification of the number of EOC stem cells in the tumor can be used as a predictor of disease and could be applied for treatment selection in early-stage ovarian cancer.

scholarly journals Inhibition of Aurora-A kinase induces cell cycle arrest in epithelial ovarian cancer stem cells by affecting NFĸB pathway

Cell Cycle ◽  
2011 ◽  
Vol 10 (13) ◽  
pp. 2206-2214 ◽  
Author(s):  
Ilana Chefetz ◽  
Jennie C. Holmberg ◽  
Ayesha B. Alvero ◽  
Irene Visintin ◽  
Gil Mor
Keyword(s):  
Cell Cycle ◽  
Ovarian Cancer ◽  
Stem Cells ◽  
Cancer Stem Cells ◽  
Epithelial Ovarian Cancer ◽  
Cell Cycle Arrest ◽  
Aurora A Kinase ◽  
Aurora A ◽  
Ovarian Cancer Stem Cells ◽  
Cycle Arrest

scholarly journals Novel Therapeutic Strategies for Ovarian Cancer Stem Cells

2020 ◽  
Vol 10 ◽  
Author(s):  
Nastassja Terraneo ◽  
Francis Jacob ◽  
Anna Dubrovska ◽  
Jürgen Grünberg
Keyword(s):  
Ovarian Cancer ◽  
Stem Cells ◽  
Cancer Stem Cells ◽  
Therapeutic Strategies ◽  
Ovarian Cancer Stem Cells ◽  
Novel Therapeutic Strategies ◽  
Novel Therapeutic

scholarly journals HER2 decreases drug sensitivity of ovarian cancer cells via inducing stem cell-like property in an NFκB-dependent way

2019 ◽  
Vol 39 (3) ◽  
Author(s):  
Wenxiang Wang ◽  
Yuxia Gao ◽  
Jing Hai ◽  
Jing Yang ◽  
Shufeng Duan
Keyword(s):  
Ovarian Cancer ◽  
Stem Cells ◽  
Stem Cell ◽  
Cancer Stem Cells ◽  
Cancer Cells ◽  
Drug Sensitivity ◽  
Ovarian Cancer Cells ◽  
Her2 Overexpression ◽  
Her2 Positive ◽  
Ovarian Cancer Stem Cells

Abstract Increasing evidence shows that cancer stem cells are responsible for drug resistance and relapse of tumors. In breast cancer, human epidermal growth factor receptor 2 (HER2) induces Herceptin resistance by inducing cancer stem cells. In the present study, we explored the effect of HER2 on cancer stem cells induction and drug sensitivity of ovarian cancer cell lines. First, we found that HER2 overexpression (HER2 OE) induced, while HER2 knockdown (HER2 KD) decreased CD44+/CD24− population. Consistently, HER2 expression was closely correlated with the sphere formation efficiency (SFE) of ovarian cancer cells. Second, we found that NFκB inhibition by specific inhibitor JSH23 or siRNA targetting subunit p65 dramatically impaired the induction of ovarian cancer stem cells by HER2, indicating that NFκB mediated HER2-induced ovarian cancer stem cells. Third, we found that HER2 KD significantly attenuated the tumorigenicity of ovarian cancer cells. Further, we found that HER2 inhibition increased drastically the sensitivity of ovarian cancer cells to doxorubicin (DOX) or paclitaxel (PTX). Finally, we examined the correlation between HER2 status and stem cell-related genes expression in human ovarian tumor tissues, and found that expressions of OCT4, COX2, and Nanog were higher in HER2 positive tumors than in HER2 negative tumors. Consistently, the 5-year tumor-free survival rate of HER2 positive patients was dramatically lower than HER2 negative patients. Taken together, our data indicate that HER2 decreases drug sensitivity of ovarian cancer cells via inducing stem cell-like property.

Sign in / Sign up

Export Citation Format

Share Document